GlassScriptPhysician profile
Rajdeep Singh Gadh
NPI 1811929144
$2,766.51
in general payments reported to CMS, 2019-2025
22 companies · $727 in 2025
The $727 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $141 · 2021: $121 · 2022: $379 · 2023: $499 · 2024: $662 · 2025: $727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,864 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,863.58 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $436.50 | 2019-2025 | Farxiga |
| Horizon Therapeutics Plc | $338.45 | 2021-2023 | Krystexxa |
| Amgen INC. | $300.90 | 2019-2024 | Tavneos, Parsabiv, Aranesp |
| Bayer Healthcare Pharmaceuticals INC. | $260.62 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $241.60 | 2022-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $194.29 | 2019-2025 | Jynarque, Voyxact |
| Novo Nordisk INC | $161.05 | 2024-2025 | Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.74 | 2023-2025 | Jardiance |
| Akebia Therapeutics INC | $117.77 | 2020-2024 | Vafseo, Auryxia |
| Novartis Pharmaceuticals Corporation | $103.42 | 2023-2025 | |
| Travere Therapeutics, INC. | $70.18 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $64.49 | 2023-2025 | Lupkynis |
| Ani Pharmaceuticals, INC. | $58.84 | 2024-2025 | Purified Cortrophin Gel |
| Nxstage Medical, INC. | $56.24 | 2019 | |
| Fresenius USA Marketing, INC. | $53.38 | 2019-2025 | Velphoro |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $53.22 | 2021-2023 | Gattex |
| Opko Pharmaceuticals, LLC | $45.03 | 2019-2025 | Rayaldee |
| Daiichi Sankyo INC. | $23.48 | 2020 | |
| Alexion Pharmaceuticals, INC. | $18.18 | 2022 | |
| Cvrx, INC. | $18.14 | 2023 | Barostim Neo System |
| Genzyme Corporation | $15.13 | 2019 | |
| Xeris Pharmaceuticals, INC. | $14.86 | 2023 | Keveyis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajdeep Gadh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.